-
E-mail
cw@avt-cn.com
-
Phone
15692161719
-
Address
Building A, 27th Floor, 838 Zhangyang Road, Pudong New Area, Shanghai
Avito (Shanghai) Pharmaceutical Technology Co., Ltd
CPHI China 2025 successfully concludes | Focusing on innovation in injection excipients, empowering drug research and development
Date: 2025-07-04Read: 0
The 23rd World Pharmaceutical Raw Materials China Exhibition (CPHI China 2025) successfully concluded on June 26th in Shanghai. As an important benchmark in the global pharmaceutical raw material field, CPHI China is a key platform for insight into industry trends, establishing cooperation networks, and evaluating innovative technologies.
Aiweituo (booth: E3E36) made another appearance at this exhibition. Our professional product sales and technical support team, with key excipients such as nucleic acid drugs, biologics, vaccine adjuvants, and medical beauty materials, has attracted over a thousand global professional visitors to come and exchange ideas, and have conducted in-depth discussions on specific challenges in research and development and production.
One of the core challenges in current drug development is to efficiently screen high-quality excipients to accelerate the development process, optimize formulation performance, and ensure smooth market launch based on scientific validation. Avito has been dedicated to this area, providing eight core product lines:
During the exhibition, the Avito team, with their profound technical accumulation and professional application support experience, discussed product features, application cases, and technical difficulties with numerous R&D colleagues. Many R&D experts have shown strong interest in our product line, especially in nucleic acid delivery, biologics, vaccine adjuvants, and medical beauty raw materials and excipients.
QS-21 extraction of freeze-dried powder
The exhibition has come to an end, and cooperation and innovation continue.
Aiweituo sincerely thanks its pharmaceutical research and development partners for their continuous attention and trust. In the future, we will steadfastly delve into the field of injectable excipients, committed to providing more comprehensive, professional, and timely technical support and customized services to global drug research and development institutions, accelerating the solution process from research and development to market launch.
We look forward to working together with all R&D experts to promote the development and breakthroughs of innovative drugs!
Last Article: Review of Avito's CDE Registration in 2024
Next Article: QS-21CDE+DMF dual reporting